NicOx.... in attesa di.....

[PIZZODIGINO]

..insomma..


o portano un progetto/obiettivo "concreto" e relativi..

• nome&cognome
• dettagli della/e operazione/i

o voglio proprio vedere chi gli da fiducia di fare e disfare una società (eufemismo per dire di poter disporre degli € che gli azionisti ci hanno messo)..

d'altronde se é stato messo in piedi cotanta presentazione per un "misero" 11,80% di una piccola sconosciuta società inglese..
e a quel tempo non si accennò nemmeno che la cosa dovesse passare attraverso una AGE..


..c'é da pensare che invertendo il ragionamento..

• se in questo caso l'AGE é stata annunciata "prima"..
• ..vorrà dire che il deal/news ..sarà moooolto più "interessante" ?

======================

pertanto o arriva big-news (credo al max nel giro di una decina di giorni..giusto per i tempi tecnici della cosa)
..o AGE é a rischio "buco nell'acqua"

Concordo con te; se non ci daranno dei nomi e cognomi, in pochi parteciperanno all'AGE e non si raggiungerà il quorum. Bisogna poi vedere se in seconda convocazione è ancora necessario il quorum.

 

[PIZZODIGINO]

First resolution


Delegation of competence to the Board of Directors to proceed with increases in share capital up to a maximum nominal amount of € 4,859,000 for a period of 26 months. Under this resolution, shareholders keep their preemptive subscription rights to the newly issued shares. This resolution includes the possibility of issuing corporate bonds up to a maximum amount € 350,000,000.

 

[PIZZODIGINO]

SUMMARY OF THE RESOLUTIONS ​

SUBMITTED TO THE APPROVAL OF THE EXTRAORDINARY SHAREHOLDER MEETING ​

CONVENED ON JULY 12, 2012​

---------------------​

First resolution


Delegation of competence to the Board of Directors to proceed with increases in share capital up to a maximum nominal amount of € 4,859,000 for a period of 26 months. Under this resolution, shareholders keep their preemptive subscription rights to the newly issued shares. This resolution includes the possibility of issuing corporate bonds up to a maximum amount € 350,000,000.

Second resolution


Delegation of competence to the Board of Directors to proceed with increases in share capital by public offer, subject to the maximum nominal amount of € 2,915,000 (and to the global nominal amount of € 4,859,000 provided for in resolution 1) for a period of 26 months. Under this resolution, shareholders renounce their preemptive subscription rights to the newly issued shares. This resolution also includes the possibility of issuing corporate bonds up to a maximum amount € 350,000,000.
(The maximum nominal amount of € 2,915,000 under this resolution applies globally to all the authorizations under resolutions 2, 3, 4 and 8.)

Third resolution


Delegation of competence to the Board of Directors to proceed with increases in share capital by private placement, subject to a maximum of 20% of the share capital (and to both (i) the nominal amount of € 2,915,000 provided for in resolution 1 and (ii) to the global nominal amount of € 4,859,000 provided for in resolution 1 for a period of 26 months. Under this resolution, shareholders renounce their preemptive subscription rights to the newly issued shares.
(The maximum nominal amount of € 2,915,000 applies globally to all the authorizations under resolutions 2, 3, 4 and 8)



Fourth resolution


Authorization for the Board, when utilizing the second or third resolutions and subject to 10% of the share capital per year, to fix the price of the shares to be issued with up to 10% discount on the last ten trading days weight average price.

Fifth resolution


[overallotment] Delegation of competence to the Board of Directors, for a period of 26 months, to increase the number of shares to be issued in the context of an increase of the share capital (with or without maintaining the shareholders preemptive subscription rights) under resolutions 1 to 4, subject to the maximum nominal amounts of :
- € 4,859,000 with respect to share capital increases under resolution 1
- € 2,915,000 with respect to share capital increases under resolutions 2 to 4
within the limit of 15% of the initial increase and under identical pricing conditions.

Sixth resolution


Delegation of competence to the Board of Directors, for a period of 26 months, to increase the share capital by incorporation of reserves and provisions subject a maximum nominal amount of € 4,859,000 (and to the global nominal amount of € 4,859,000 provided for in resolution 1).

Seventh resolution


Delegation of powers to the Board of Directors, for a period of 26 months, to increase the share capital, within the limit of 10% of said share capital, to remunerate capital contributions in kind consisting in securities of another entity.


Eighth resolution


(PIPE) Delegation of competence to the Board of Directors, subject to the maximum nominal amount of € 2,915,000 and for a period of 18 months, to issue securities, the shareholders’ preferential right of subscription being suppressed, for the benefit of companies or investment funds investing in the pharmaceutical/biotech sector, either French or foreign.
- weight average price calculation: 5 trading days prior to issuance;
- maximum authorized discount: 10%;
- maximum number of investors subscribing to the offer: 50.
This resolution is subject to the maximum nominal amount of € 4,859,000 provided for in resolution 1 and to the maximum nominal amount of € 2,915,000 provided for in resolution 2. It further allows to issue debt securities giving right to shares of the Company subject to a maximum of € 50 million.
(The maximum nominal amount of € 2,915,000 applies globally to all the authorizations under resolutions 2, 3, 4 and 8)


Ninth resolution


Delegation of competence to the Board of Directors, for a period of 26 months, to proceed with increases in share capital up to a maximum nominal amount of € 60,000 in connection with profit sharing plans reserved for the Company’s employees.
This resolution is subject to the maximum nominal amount of € 4,859,000 provided for in resolution 1.

Tenth resolution​

Delegation of powers to the Board of Directors to issue, within one year of the shareholder meeting, up to 20,000 warrants for the benefit of each of Ms. Norinder and Messrs. Buus Lassen, Labbé, Kailian and Samuelsson, (which is a total of up to 100,000 warrants), allocated gratuitously, giving each beneficiary the right to subscribe, at a fixed price, up to 20,000 new shares of the company, (which is a total of up to 100,000 new shares) each warrant thus giving right to subscribe one new share with a par-value of € 0.2.

The Board is granted the power to:
- issue the warrants,
- fix their price of issuance, characteristics and conditions of issuance and exercise,
- determine the price and conditions of subscription of the shares to be issued following the exercise of rights on the warrants, it being specified that the price of issuance of the shares will be no less than the average trading price of NicOx stock for the 20 trading days preceding the issuance of the warrants,
- acknowledge the increase in capital subsequent to the exercise of warrant rights and correlatively modify the by-laws.
The exercise of the warrants is subject to the achievement of the following performance criteria: achievement of 70% of the Company objectives over at least a two year period, except that the Board may modify such performance criteria in the event of a change of control of NicOx or of merger of NicOx into a third party entity.

​

Eleventh resolution​

​

Modification of the by-laws to provide that the term of office of Board members and observers be reduced from six years to four years (would not apply to ongoing terms of office).

Twelfth resolution​

Modification of the by-laws to broaden the business purpose of the Company to include the marketing and distribution (including wholesale) of drugs, medical devices, food supplements, notably by means of exportation.

​

Thirteenth resolution​

Modification of the by-laws to update the conditions of representation of the shareholders at shareholder meetings (notably to allow them to appoint any person or legal entity to vote in their name).

Fourteenth resolution​

Authorization granted to the Board of Directors, for a period of 38 months, to grant to employees and corporate officers of the group the right to obtain free shares within the limit of 1,500,000 new or existing shares, it being specified that nominal increase in share capital under this resolution may not exceed € 300,000. The obtaining of the shares is subject to the achievement of the following performance criteria: achievement of 70% of the Company objectives over at least a two year period, except that the Board may modify such performance criteria in the event of a change of control of NicOx or of merger of NicOx into a third party entity.

The Board may choose between two possibilities:
- the attribution of shares to the beneficiaries would only become firm at the expiry of a minimum three year period and, subsequently, the shares may not be sold before an additional minimum two year period;
- the attribution of shares to the beneficiaries would only become firm at the expiry of a minimum four year period in which case the shares may then be sold immediately.
These time limits may be extended by the Board of Directors.

Fifteenth resolution​

Authorization granted to the Board of Directors for a period of 38 months to grant to employees and corporate officers of the group, stock options giving right to subscribe up to 1,500,000new or existing shares, it being specified that nominal increase in share capital under this resolution may not exceed € 300,000. The subscription price of the shares may not be less than the average trading price of NicOx stock during the 20 days prior to the day of attribution of the stock-options. The exercise of the stock-options is subject to the achievement of the following performance criteria: achievement of 70% of the Company objectives over at least a two year period, except that the Board may modify such performance criteria in the event of a change of control of NicOx or of merger of NicOx into a third party entity.

This resolution replaces the resolution voted by the 2009 shareholder meeting.

Sixteenth resolution​

Power for legal formality requirements.

* * *​

​

 

[magolibero]

First resolution


Delegation of competence to the Board of Directors to proceed with increases in share capital up to a maximum nominal amount of € 4,859,000 for a period of 26 months. Under this resolution, shareholders keep their preemptive subscription rights to the newly issued shares. This resolution includes the possibility of issuing corporate bonds up to a maximum amount € 350,000,000.

tutti i documenti QUI ..

ma come detto prima , rischiano di non servire a niente ..se nel frattempo non saltano fuori dei nomi&cognomi di come spenderli

..se non addirittura sono a rischio di un "assalto" del tipo di quello che é successo a QLTI => vedi QUI

 

[PIZZODIGINO]

tutti i documenti QUI ..

ma come detto prima , rischiano di non servire a niente ..se nel frattempo non saltano fuori dei nomi&cognomi di come spenderli

..se non addirittura sono a rischio di un "assalto" del tipo di quello che é successo a QLTI => vedi QUI

Hai ragione; ci voglio fatti concreti per autorizzare degli aumenti di capitale; io in linea di principio sono favorevole ad un aumento con emissione di nuove azioni da dare in cambio agli azionisti della società da acquisire; non darò la mia approvazione ad un aumento a pagamento.

 

[PIZZODIGINO]

E' inutile negare che siamo un pò confusi a seguito della convocazione dell'AGE.
Speriamo davvero che prima del 12 luglio ci sia l'annuncio di una nuova società da acquisire.

 

[relavo]

Precommento: se stà cappellata di comunicato lo distribuivano ieri non era meglio? Ci si risparmiava un bel -10%, che capisco al pirlotto gli rimbalza ampiamente, tanto stà sulle nostre spalle, ma a noi non ci sarebbe dispiaciuto fare qualche soldino come tutti gli altri.

Commenti:
1) Non capisco il casino che stanno facendo per un aumento di capitale di meno di 5 milioni.

2) Non perdono l'occasione per distribuirsi stock options e warrants.... mai una riduzione. Io proporrei invece la distribuzione di stock options, fortemente controllata e legata ai risultati, per i nuovi assunti ed un decremento delle stock options acquisite in passato dal management vecchio equivalente alla perdita di valore dell'azione conseguente all'insuccesso del napro, cosi', giusto per essere corretti ed onesti verso l'azienda, l'azionariato ed il mercato.

Pirlottino, se sei davvero il gentil'uomo che tutti dicono, dimostraci come sei corretto.

 

[tradermen]

SUMMARY OF THE RESOLUTIONS ​

SUBMITTED TO THE APPROVAL OF THE EXTRAORDINARY SHAREHOLDER MEETING


CONVENED ON JULY 12, 2012


---------------------​

First resolution


Second resolution


Third resolution



Fourth resolution

.

Fifth resolution


Sixth resolution

Seventh resolution



Eighth resolution


Ninth resolution

Tenth resolution


2.
This resolution replaces the resolution voted by the 2009 shareholder meeting.

Sixteenth resolution​

Power for legal formality requirements.

* * *​

si gioca al lotto??...

 

[tradermen]

Precommento: se stà cappellata di comunicato lo distribuivano ieri non era meglio? Ci si risparmiava un bel -10%, che capisco al pirlotto gli rimbalza ampiamente, tanto stà sulle nostre spalle, ma a noi non ci sarebbe dispiaciuto fare qualche soldino come tutti gli altri.

Commenti:
1) Non capisco il casino che stanno facendo per un aumento di capitale di meno di 5 milioni.

.

nn lo capisco ank'io?....ma quanto è il valore nominale dell' azione? ci sarà sovraprezzo penso..

 

[magolibero]

nn lo capisco ank'io?....ma quanto è il valore nominale dell' azione? ci sarà sovraprezzo penso..

..appunto..

..tutto 'sto cinema..che non ha senso senza un nome&cognome a cui sia funzionale